Psychiatric Times

01/25/2026

Lifestyle psychiatry offers an evidence-based, low-risk, and cost-effective third pillar of care alongside psychotherapy and medication for major depressive disorder. Here's how lifestyle strategies can be integrated within a stepped care model. https://www.psychiatrictimes.com/view/lifestyle-psychiatry-for-supporting-individuals-with-major-depressive-disorder

01/24/2026

Nutrition discussions can offer valuable insight into patients’ emotional lives, identities, and daily routines. Eating behaviors often mirror underlying feelings, revealing patterns of avoidance, control, neglect, or care. https://www.psychiatrictimes.com/view/integrating-nutritional-guidance-into-psychiatric-practice

01/23/2026

For patients with schizophrenia spectrum disorders, even small amounts of physical activity (ie, less than 150 minutes of moderate to vigorous physical activity) may confer benefits.

Psychiatric Times is the connection to Psychiatry and Mental Health, featuring clinical updates, expert views, and research news in multimedia formats.

01/22/2026

❄️ Need some winter reading? The entire January issue of Psychiatric Times is now live on our website. Read it here: https://www.psychiatrictimes.com/journals/psychiatric-times/vol-43-issue-1

01/21/2026

💰✂️On late Tuesday January 13, the government cut off approximately $2 billion in federal grant money for national mental health and addiction programs. Then, in a rapid reversal, they restored the money on Wednesday night.

Government funding cuts to mental health and addiction programs create chaos, prompting swift restoration amid widespread concern from advocacy groups. Read the statement from the AFSP here.

01/20/2026

💊 BioXcel Therapeutics has submitted a supplemental New Drug Application to the FDA for dexmedetomidine (Igalmi) for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the outpatient setting.

BioXcel Therapeutics submits an sNDA to the FDA for Igalmi to treat agitation in bipolar disorder and schizophrenia at home.

01/16/2026

A new analysis of phase 3 data has found that lumateperone (Caplyta), in combination with an antidepressant, showed significantly greater remission rates in adults with major depressive disorder than placebo plus an antidepressant at 6 weeks, with continued benefits observed through 6 months in an open-label extension study.
https://www.psychiatrictimes.com/view/new-phase-3-data-analysis-lumateperone-shows-promise-for-remission-of-major-depressive-disorder

01/15/2026

The first patient has been dosed in Axsome Therapeutics' FORWARD phase 3 trial of esreboxetine (AXS-14) for the management of fibromyalgia. https://www.psychiatrictimes.com/view/first-patient-dose-in-phase-3-trial-of-axs-14-for-treatment-of-fibromyalgia

01/14/2026

🤖🧠 AI in health care offers precision in diagnosis and treatment, but raises ethical concerns regarding privacy and transparency. Let's demystify the mechanism behind the magic.

Explore the transformative impact of artificial intelligence on modern life, from health care advancements to productivity enhancements and ethical considerations.

01/13/2026

🚨💉The FDA has requested that drug application holders remove information regarding the risk of suicidal ideation and behavior from the labeling of GLP-1 RA medications, including liraglutide (Saxenda), semaglutide (Wegovy), and tirzepatide (Zepbound). https://www.psychiatrictimes.com/view/fda-issues-removal-of-suicidal-behavior-and-ideation-warning-from-glp-1-ras

01/12/2026

🧠⚡The FDA has approved 's ProlivRx, the first prescription, physician-directed, at-home brain neuromodulation therapy as an adjunctive treatment for adults with MDD who failed to achieve satisfactory improvement from at least 1 previous antidepressant. https://www.psychiatrictimes.com/view/fda-approves-prolivrx-first-prescription-physician-directed-at-home-brain-neuromodulation-therapy-for-mdd

01/12/2026

An independent Data Safety Monitoring Board review of the ongoing phase 3 clinical trial evaluating LPCN 1154 for the rapid relief treatment of postpartum depression recommended that the trial continue as planned with no modifications.

Lipocine's LPCN 1154 shows promise in treating postpartum depression, with a strong safety profile and potential for rapid relief in outpatient settings.